Technical Analysis for KRON - Kronos Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.51% | |
| Bollinger Band Squeeze | Range Contraction | 0.51% | |
| NR7 | Range Contraction | 0.51% | |
| Narrow Range Bar | Range Contraction | 0.51% | |
| Fell Below 20 DMA | Bearish | -1.31% | |
| New Downtrend | Bearish | -1.31% | |
| Bollinger Band Squeeze | Range Contraction | -1.31% | |
| Gapped Up | Strength | -1.31% | |
| Crossed Above 20 DMA | Bullish | -3.29% | |
| Bollinger Band Squeeze | Range Contraction | -3.29% |
| Alert | Time |
|---|---|
| Possible NR7 | about 2 hours ago |
| Up 1% | about 5 hours ago |
| Fell Below Previous Day's Low | about 6 hours ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 1% | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/21/2024
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Solid Tumors Acute Myeloid Leukemia Enzymes Tyrosine Kinase Transcription Transcription Factors Cancer Therapeutics Novel Cancer Transcription Factor Cyclin Dependent Kinase Entospletinib Morpholines
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Solid Tumors Acute Myeloid Leukemia Enzymes Tyrosine Kinase Transcription Transcription Factors Cancer Therapeutics Novel Cancer Transcription Factor Cyclin Dependent Kinase Entospletinib Morpholines
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.29 |
| 52 Week Low | 0.731 |
| Average Volume | 427,930 |
| 200-Day Moving Average | 1.18 |
| 50-Day Moving Average | 1.12 |
| 20-Day Moving Average | 1.01 |
| 10-Day Moving Average | 1.02 |
| Average True Range | 0.07 |
| RSI (14) | 38.27 |
| ADX | 26.56 |
| +DI | 9.13 |
| -DI | 20.24 |
| Chandelier Exit (Long, 3 ATRs) | 0.94 |
| Chandelier Exit (Short, 3 ATRs) | 1.12 |
| Upper Bollinger Bands | 1.07 |
| Lower Bollinger Band | 0.95 |
| Percent B (%b) | 0.26 |
| BandWidth | 11.57 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.03 |
| MACD Histogram | 0.0032 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.02 | ||||
| Resistance 3 (R3) | 1.03 | 1.02 | 1.02 | ||
| Resistance 2 (R2) | 1.02 | 1.01 | 1.02 | 1.02 | |
| Resistance 1 (R1) | 1.00 | 1.00 | 1.00 | 1.00 | 1.01 |
| Pivot Point | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 |
| Support 1 (S1) | 0.97 | 0.98 | 0.97 | 0.97 | 0.95 |
| Support 2 (S2) | 0.96 | 0.97 | 0.96 | 0.95 | |
| Support 3 (S3) | 0.94 | 0.96 | 0.95 | ||
| Support 4 (S4) | 0.94 |
